Grease composition with UVB damage repairing effect and application thereof

Abstract

The invention provides UVB damage repair application of a grease composition containing safflower seed oil and fermented artemisia apiacea oil. The fermented artemisia apiacea oil is prepared by the following steps: (a) carrying out supercritical CO2 extraction on artemisia apiacea medicinal materials; (b) fermenting, namely fermenting by adopting bifidus yeast; (c) separating to obtain fermented artemisia apiacea oil; wherein the bifidobacterium is selected from bifidobacterium adolescentis, bifidobacterium animalis subspecies, bifidobacterium animalis subspecies lactis, bifidobacterium bifidum, bifidobacterium breve, bifidobacterium longum subspecies longum or bifidobacterium longum subspecies infantis. The invention further relates to application of the grease composition containing the safflower seed oil and the fermented artemisia apiacea oil in preparation of a skin external preparation with a UVB damage repairing effect.

Description

Technical Field

[0001] This invention relates to the field of cosmetics, and more specifically to an oil composition with UVB damage repair function and its application. Background Technology

[0002] The pathogenesis mechanism of ultraviolet radiation exhibits exposure pattern dependence characteristics. Short-term effects can cause sunburn or allergic reactions, while long-term chronic cumulative radiation drives squamous cell carcinoma through dose-dependent DNA damage, and acute photodamage caused by intermittent pulsed exposure is significantly associated with the risk of melanoma.

[0003] Artemisia annua L., a traditional Chinese medicine, was first recorded in the "Fifty-Two Prescriptions" and has since been included in several other herbal classics. It is widely distributed in Chongqing, Anhui, Hubei, Shandong, and other regions of my country. Artemisia annua is primarily used in traditional Chinese medicine to treat fever and colds, and is documented in the "Shennong's Classic of Materia Medica," "Elbow-Side Emergency Prescriptions," and "Compendium of Materia Medica." Artemisia annua L. possesses heat-clearing, detoxifying, blood-cooling, and stomach-strengthening effects, and contains various bioactive components such as flavonoids, polysaccharides, polyphenols, and volatile oils.

[0004] Safflower seed oil is derived from the seeds of safflower (Carthamus tinctorius L.), a plant in the Asteraceae family. After extraction, it retains a high concentration of linoleic acid. This ω-6 essential fatty acid is not only an important component of lipids in the skin barrier, but it can also improve the water retention capacity by regulating the lipid arrangement of the stratum corneum. However, existing studies lack sufficient molecular evidence for its role in regulating the dynamic regulation of lipid metabolism in skin damage.

[0005] my country possesses abundant resources of traditional Chinese medicinal herbs, and numerous studies have reported the extraction of cosmetic ingredients with significant skincare benefits through the microbial fermentation of these herbs. However, research on the fermentation and utilization of Artemisia annua is relatively limited.

[0006] This invention is the first to explore the repair effects and specific mechanisms of fermented artemisia annua oil and safflower seed oil after UVB exposure, and also provides their application in the field of skincare products. Summary of the Invention

[0007] On one hand, the present invention provides an application of an oil composition comprising safflower seed oil and fermented artemisia annua oil for UVB damage repair, wherein the fermented artemisia annua oil is prepared by the following method:

[0008] (a) Artemisia annua was extracted using supercritical CO2 extraction;

[0009] (b) Fermentation, using Bifida ferment lysate;

[0010] (c) Fermented artemisia oil was obtained after separation;

[0011] The bifida ferment lysate is a bifidobacterium, selected from: Bifidobacterium adolescentis, Bifidobacterium animalis subsp. animalis, Bifidobacterium animalis subsp. lactis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum subsp. longis, or Bifidobacterium longum subsp. infantis.

[0012] In a preferred embodiment, the fermented artemisia oil contains artemisinin acid at a content ≥0.03% by weight, has an acid value ≤2.5 mg / g, a peroxide value ≤0.650 g / 100g, and a density of 0.9-0.95 g / cm³. 3 .

[0013] In a preferred embodiment, the relative content of linoleic acid in the fatty acid composition of the fermented artemisia annua oil is ≥35% by weight, and the content of artemisinin in the fermented artemisia annua oil is ≥0.05% by weight.

[0014] In a preferred embodiment, the weight ratio of safflower seed oil to fermented artemisia oil in the oil composition is 1:1 to 3:1.

[0015] In a preferred embodiment, the application includes one or more of the following:

[0016] (i) Inhibits skin edema and reduces desquamation after UVB exposure;

[0017] (ii) Alleviate abnormal thickening of the epidermis caused by UVB;

[0018] (iii) Downregulating VEGF pathway activity inhibits inflammatory response and reduces barrier function damage;

[0019] (iv) Activating the expression of ECM-related genes remodels the collagen network and restores skin structural homeostasis;

[0020] (v) Synergistically regulate macrophage chemotaxis or activation pathways to exert anti-inflammatory effects;

[0021] (vi) Inhibit the expression of inflammatory factors IL-6, IL-1β and TNF-α.

[0022] On the other hand, the present invention also relates to the use of an oil composition comprising safflower seed oil and fermented artemisia annua oil in the preparation of a topical skin agent with UVB damage repair function, wherein the fermented artemisia annua oil is prepared by the following method:

[0023] (a) Artemisia annua was extracted using supercritical CO2 extraction;

[0024] (b) Fermentation, using Bifida ferment lysate;

[0025] (c) Fermented artemisia oil was obtained after separation;

[0026] The bifida ferment lysate is a bifidobacterium, selected from: Bifidobacterium adolescentis, Bifidobacterium animalis subsp. animalis, Bifidobacterium animalis subsp. lactis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum subsp. longis, or Bifidobacterium longum subsp. infantis.

[0027] In a preferred embodiment, the weight ratio of safflower seed oil to fermented artemisia oil in the oil composition is 1:1 to 3:1.

[0028] In a preferred embodiment, the content of the oil composition in the topical skin agent is 0.001-100% by weight, preferably 0.01-5% by weight.

[0029] In a preferred embodiment, the topical skin agent is selected from: face cream, lotion, gel, toner, serum, face mask, eye cream, aerosol cleansing foam, spray, shower gel, or facial cleanser. Brief description of the attached figures

[0030] Figure 1 The results of photographs taken on days 0, 1, 3, 5, and 7 show the results of the ultraviolet irradiation control group (UV-CON) and each ultraviolet irradiation group (including UV+safflower seed oil, UVB+fermented artemisia oil, UV+(safflower seed oil:fermented artemisia oil = 1:1), UV+(safflower seed oil:fermented artemisia oil = 3:1)).

[0031] Figure 2 Microscopic images of the normal control group (no UV), the ultraviolet irradiation control group (UV-CON), and various ultraviolet irradiation groups (including UV+safflower seed oil, UVB+fermented artemisia oil, UV+(safflower seed oil:fermented artemisia oil = 1:1), UV+(safflower seed oil:fermented artemisia oil = 3:1)) are shown.

[0032] Figure 3 The epidermal thicknesses of the normal control group (no UV), the UV-CON control group, and each UV-CON irradiation group (including UV + safflower seed oil, UVB + fermented artemisia oil, UV + (safflower seed oil: fermented artemisia oil = 1:1), UV + (safflower seed oil: fermented artemisia oil = 3:1)) are shown. Epidermal thickness ratios were obtained by normalizing the mean of the control group and comparing the epidermal thicknesses of other groups to the mean of the control group. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, ns indicates no statistical significance.

[0033] Figure 4-10The transcriptomics results are displayed. The X and Y axes represent the new datasets obtained after dimensionality reduction of sample expression levels, corresponding to the principal components, used to represent the differences between samples; the values ​​in parentheses of the axis labels represent the percentage of the overall variance explained by the corresponding principal component. Points represent each sample, and the same color represents the same sample group. PV stands for Proportion of variance, and SD stands for Standard Deviation.

[0034] Figure 11 The immunofluorescence results are shown. The results indicate that sample group 3 effectively reversed the UVB-induced upregulation of F4 / 80 expression, suggesting that sample group 3 can exert its anti-inflammatory effect by synergistically regulating macrophage chemotaxis or activation pathways.

[0035] Figure 12 The study showed the effect of sample group 3 on the gene expression levels of IL-1β, IL-6, and TNF-α. Detailed Implementation

[0036] This invention is the first to discover that an oil composition of fermented artemisia oil and safflower seed oil obtained by fermenting artemisia oil with Bacillus subtilis as a strain has a skin repair effect against UVB damage, and is particularly suitable for the preparation of cosmetic compositions with skin repair effects.

[0037] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. While any methods and materials similar or equivalent to those described herein may be used to practice or test the invention, preferred methods and materials are described herein. For the purposes of this invention, the following terms are defined.

[0038] As used herein, the term "about" means a quantity, level, value, dimension, size, or amount that differs from that of a reference by as much as 30%, 20%, or 10%. Percentages used herein, unless otherwise stated, are by weight.

[0039] Throughout this specification and claims, unless otherwise required, the words “comprising” and its variations “containing” and “including” shall be understood to mean including the said whole or step, or a group of whole or steps, but not excluding any other whole or step, or other group of whole or steps.

[0040] Oil and fat composition

[0041] This invention provides an oil composition comprising safflower seed oil and fermented artemisia annua oil.

[0042] This invention uses fermented artemisia annua oil purchased from Hangzhou Shiguang Xinya Biotechnology Co., Ltd., commercially known as Bifida ferment lysate fermented artemisia annua oil. The artemisia annua oil of this invention is obtained by fermenting artemisia annua oil using Bifida ferment lysate as the inoculum. In this application, four different batches of fermented artemisia annua oil will be used for experiments: batch 1, batch 2, batch 3, and batch 4.

[0043] The fermented artemisia oil in this application is obtained by separating artemisia annua medicinal material through supercritical CO2 extraction and fermentation with Bifidobacterium bifida. The Bifidobacterium bifida strain is Bifidobacterium bifidum, including any one or more of Bifidobacterium adolescentis, Bifidobacterium animalis subsp. Animalis, Bifidobacterium animalis subsp. Lactis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum subsp. Longum, and Bifidobacterium longum subsp. infantis.

[0044] In a specific embodiment, the artemisinin acid content in the fermented artemisia oil of the present invention is ≥0.03% by weight, the acid value of the fermented artemisia oil is ≤2.5 mg / g, the peroxide value of the fermented artemisia oil is ≤0.650 g / 100g, and the density of the fermented artemisia oil is 0.9-0.95 g / cm³. 3 .

[0045] In embodiments of the present invention, the fatty acid composition of the fermented artemisia annua oil is greater than 90% by weight. In embodiments of the present invention, the relative content of linoleic acid in the fatty acid composition of the fermented artemisia annua oil is ≥35% by weight, preferably ≥45% by weight.

[0046] In an embodiment of the present invention, the content of artemisinin in the fermented artemisia oil is ≥0.03% by weight, preferably ≥0.05% by weight.

[0047] GC-MS analysis of fermented artemisia annua oil revealed a total of 54 compounds, including lipids, aldehydes, terpenes, sterols, vitamins, and others. Mass content analysis showed that fatty acid glycerides were the dominant compounds (93.4%-99.4%), with other trace components including squalene (0.01%-0.02%), vitamin E (0.02%-0.04%), and γ-sitosterol (0.08%-0.14%). Further relative mass content analysis revealed three aldehydes, including 2-heptenal, trans-2-decenal, and a high content of trans-2,4-decadienal (7.38%); six terpenoids, represented by β-caryophyllene (8.97%), β-serlingene, and caryophyllin; and three sterols, with γ-sitosterol (6.52%), campesterol (10.11%), and stigmasterol (5.36%) forming the sterol system. Vitamin E (3.99%) was the only vitamin component detected. Notably, the triterpenoid cycloartenol was the most abundant component at 40.27%, while α-amyrin and 24-methylenecycloartenol further enriched the diversity of terpenoids. Other components included organic acids such as hydroxyvaleric acid and sesquiterpene lactones such as artemisinin b (1.53%), collectively forming a complex component system.

[0048] In addition, fermented artemisia annua oil contains dozens of fatty acids. The saturated fatty acids are mainly palmitic acid (C16:0, 5.87%), stearic acid (C18:0, 3.49%), and behenic acid (C22:0, 0.749%). Oleic acid (C18:1n9c, 26.1%) is the dominant monounsaturated fatty acid. Among polyunsaturated fatty acids, linoleic acid (C18:2n6c, 53%) is the most abundant component, followed by α-linolenic acid (C18:3n3, 0.11%), while γ-linolenic acid (C18:3n6) is present in low amounts (≤0.0026%). Furthermore, trace amounts of long-chain fatty acids such as arachidic acid (C20:0, 0.259%) and lignotaric acid (C24:0, 0.259%) were also detected in the fatty acid glycerides.

[0049] Safflower seed oil was purchased from Shanghai Zhongrui Biotechnology Co., Ltd., under the trade name Carthamus tinctorius seed oil. GC-MS analysis identified 42 characteristic compounds, including lipids, aldehydes, and terpenes. Lipid components were mainly glycerol derivatives, with 2-linoleylglycerol monoester (57.10%) being the most abundant, followed by glyceryl trilinoleate (19.54%) and ethyl linoleate (5.33%). Other structurally diverse components, such as free fatty acid linoleic acid (5.28%) and glycidyl palmitate (4.11%), were also detected. Aldehydes were mainly trans-2,4-decadienal (0.99%) and 2,4-decadienal (0.70%), while only betulinol (1.69%) was detected among terpenes. In addition, trace components such as 1,2-dipalmitin (0.56%) and glyceryl monooleate (0.37%) further enriched the complexity of the lipid profile, indicating that the lipid composition of safflower seed oil is centered on high content of glycerides, and has both structural complexity and potential functional characteristics.

[0050] Further analysis of its fatty acids showed that the fatty acid composition of safflower seed oil exhibited significant unsaturated characteristics, with linoleic acid (C18:2n6c) accounting for 69.1%, and together with oleic acid (C18:1n9c, 18.7%), forming a total unsaturated fatty acid system of 88.7%, while also containing a small amount of the essential fatty acid α-linolenic acid (Table 3-1-1-2).

[0051] Topical skin agents

[0052] The oil composition of the present invention can be used as an efficacy additive in topical skin agents to improve skin condition.

[0053] In some embodiments, the oil composition is present in the topical skin agent at a concentration of 0.001-20% by weight, preferably 0.01-5% by weight.

[0054] In some embodiments, the concentration of the oil composition used is at least 0.01% by weight. In some embodiments, the concentration of the oil composition used is 0.01-1% by weight, preferably 0.01-0.5% by weight. In preferred embodiments, the concentration of the oil composition used is 0.02-0.25% by weight. In some embodiments, the concentration of the oil composition used is 0.02-0.1% by weight. In specific embodiments, the concentration of the oil composition used is 0.03% by weight. In some embodiments, the concentration of the oil composition used is 0.1-0.25% by weight.

[0055] In some embodiments, the topical skin agent is selected from: face creams, lotions, gels, toners, serums, face masks, eye creams, aerosols (cleansing foams), shower gels, and facial cleansers. Different dosages are added depending on the type of formulation.

[0056] The term "topical skin agent" is a general term encompassing all ingredients typically used on the external surface of the skin, such as cosmetic compositions. These cosmetic compositions can include basic cosmetics, facial makeup cosmetics, body cosmetics, hair care cosmetics, etc., with no specific restrictions on their dosage forms; they can be rationally selected according to different purposes. Depending on the dosage form and purpose, these cosmetic compositions may also contain different cosmetically permissible media or matrix excipients.

[0057] Topical skin preparations contain dermatologically acceptable carriers or mediators (e.g., lotions, creams, ointments, cleansers, etc.). Those skilled in the art can select carriers capable of dissolving or dispersing these components at the concentrations described above, based on common knowledge in the art. When using a carrier, it should not cause inactivation of the oil-based composition and should not produce any adverse effects on the skin during application.

[0058] Those skilled in the art can select suitable carriers based on common knowledge and their ability to dissolve or disperse in the active component at the concentration most suitable for processing, such as water, alcohols, oils, etc.

[0059] The topical skin agents of the present invention can be in the form of topical application products that can be applied externally to the skin and can be prepared using common techniques known in the art. The carrier can have various practical forms, such as creams, dressings, gels, lotions, ointments, or liquids, including compositions that are applied and washed off, and materials incorporated into them using methods known in the art, such as dry or wet applicators, hydrogel matrices, or adhesive (or non-adhesive) patches. Preferably, the carrier is a gel or a moisture-enhancing lotion, or an applicator in dry or wet form.

[0060] Typical carriers include emulsions containing water and / or alcohols and emollients, where the emollients are, for example, oils and waxes of hydrocarbons, silicone oils, hyaluronic acid, fats or oils from plants, animals, or marine organisms, glyceryl ester derivatives, fatty acids, or fatty acid esters or alcohols or alcohol ethers, lanolin and its derivatives, polyols or esters, wax esters, sterols, phospholipids, etc., and generally include emulsifiers (nonionic, cationic, or anionic), although some emollients themselves have emulsifying properties. Additionally, these same components can be formulated into creams, gels, or solid bars by utilizing different proportions of their components and / or by incorporating thickeners such as gums or other forms of hydrophilic colloids.

[0061] The topical skin formulation of the present invention may include additional components commonly found in skin care compositions, such as emollients, skin conditioners, emulsifiers, preservatives, antioxidants, fragrances, chelating agents, etc., provided that they are physically and chemically compatible with other components in the topical skin formulation and do not affect the efficacy of the oil composition of the present invention.

[0062] In some embodiments of the topical skin formulation of the present invention, one or more preservatives may be used. Suitable preservatives include p-hydroxyacetophenone, C1-C4 alkyl p-hydroxybenzoate, and phenoxyethanol. Based on the total weight of the composition, the amount of preservative used is from about 0.5 to about 2% by weight, preferably from about 0.5 to 1% by weight.

[0063] In one example of the topical skin preparation of the present invention, one or more antioxidants may be used. Suitable antioxidants include butylated hydroxytoluene (BHT), ascorbyl palmitate (BHA), butylated hydroxyanisole, phenyl-α-naphthylamine, hydroquinone, propyl gallate, nordihydroguaiac acid, vitamin E or a derivative of vitamin E, vitamin C and its derivatives, calcium pantothenate, green tea extract, and mixed polyphenols, as well as mixtures of the substances described above. The antioxidant used is approximately 0.02 to 0.5% by weight of the total weight of the composition, more preferably in the range of approximately 0.002 to 0.1% by weight.

[0064] In one example of the topical skin preparation of the present invention, one or more emollients may be used, which, by virtue of their ability to remain on the skin surface or in the stratum corneum, act as lubricants to reduce exfoliation and improve the appearance of the skin. Typical emollients include fatty esters, fatty alcohols, mineral oils, polyether silicone copolymers, and the like. Examples of suitable emollients, not limited to, include polypropylene glycol (“PPG”)-15 octadecyl ether, PPG-10 hexadecyl ether, Steareth-10, Oleth-8, PPG-4 dodecyl ether, vitamin E acetate, lanolin, cetyl alcohol, cetearyl alcohol ethylhexanoate, cetearyl alcohol, glyceryl stearate, octyl hydroxystearate, dimethyl polysiloxane, and combinations thereof. Cetyl alcohol, cetearyl alcohol ethylhexanoate, cetearyl alcohol, glyceryl stearate, and combinations thereof are preferred. When used, the emollient is applied in an amount ranging from about 0.1% to about 30% by weight, preferably from about 1% to about 30% by weight, based on the total weight of the composition.

[0065] In one example of the topical skin preparation of the present invention, one or more moisturizers may be used. Moisturizers, also known as humectants, help enhance the effectiveness of emollients, reduce exfoliation, stimulate the removal of scaly skin, and improve skin feel. Polyols may be used as moisturizers, including, but not limited to, glycerin, polyalkylene glycols, alkylene polyols and their derivatives, including butylene glycol, propylene glycol, dipropylene glycol, glycerol, polyethylene glycol and their derivatives, sorbitol, hydroxypropyl sorbitol, hexanediol, 1,3-dibutylene glycol, 1,2,6-hexanetriol, ethoxylated glycerin, propoxylated glycerin, and combinations thereof. When used, the amount of moisturizer is from about 0.1% to about 20% by weight, preferably from about 1% to about 15% by weight, based on the total weight of the composition.

[0066] In one example of the topical skin formulation of the present invention, one or more emulsifiers may be used. The emulsifier may be used within a range of effective stable amounts. Preferably, the emulsifier is used at an amount of about 1.0 to about 10.0% by weight, more preferably about 3.0 to about 6.0% by weight, based on the total weight of the composition. Any emulsifier compatible with the components in the composition may be used. Suitable emulsifiers include stearic acid, cetyl alcohol, glyceryl stearate, lecithin, octadecyl alcohol, Steareth-2, Steareth-20, acrylate / C10-30 alkanol acrylate crosspolymers, and combinations thereof.

[0067] In one example of the topical skin formulation of the present invention, one or more pH adjusters may be used. Beneficial pH adjusters in the topical skin formulation of the present invention include tromethamine. When used, the amount of pH adjuster is approximately 0.1 to approximately 2% by weight, preferably approximately 0.1 to approximately 1% by weight, based on the total weight of the composition.

[0068] In one specific embodiment of the invention, the topical skin agent comprises an acrylate / C10-30 alkanol acrylate crosspolymer, glycerin, p-hydroxyacetophenone, glyceryl stearate and lecithin, cetearyl alcohol, cetearyl ethylhexanoate, tromethamine or a combination thereof.

[0069] In some embodiments of the present invention, the amount of oil composition in the topical skin agent is 0.001%-20% (w / w), preferably 0.01%-20% (w / w), more preferably 0.01%-10% (w / w), and most preferably 0.1%-5% (w / w).

[0070] In one specific embodiment of the present invention, the amount of the oil composition in the topical skin agent is 0.1-5% by weight. In a preferred embodiment, the amount of the oil composition in the topical skin agent is 0.13% by weight.

[0071] Example

[0072] The present invention will be further illustrated below with reference to specific embodiments. It is important to note that these embodiments are for illustrative purposes only and should not be construed as limiting the scope of protection of the invention. Those skilled in the art can make non-essential improvements and adjustments based on the above description of the invention. Test methods in the following embodiments that do not specify specific conditions are generally performed under conventional conditions or as recommended by the manufacturer. Unless otherwise stated, all percentages and parts are by weight.

[0073] Example 1: Component analysis of fermented artemisia annua oil

[0074] (The method refers to the normalization method, the third method in GB 5009.168-2016)

[0075] Weigh 0.1 g to 10 g of fermented artemisia annua oil into a 250 mL flat-bottomed flask, add approximately 100 mg of pyrogallol, a few boiling chips, and 2 mL of 95% ethanol, and mix well. Add 10 mL of hydrochloric acid solution and mix well. Place the flask in a water bath at 70℃ to 80℃ for 40 min to hydrolyze. Shake the flask every 10 min to incorporate particles adhering to the flask wall into the solution. After hydrolysis, remove the flask and cool to room temperature. Add 8 mL of 2% sodium hydroxide methanol solution to the hydrolysate, connect a reflux condenser, and reflux in a water bath at 80℃ ± 1℃ until the oil droplets disappear. Add 7 mL of 15% boron trifluoride methanol solution from the top of the reflux condenser, and continue reflux in a water bath at 80℃ ± 1℃ for 2 min. Rinse the reflux condenser with a small amount of water. Stop heating, remove the flask from the water bath, and quickly cool to room temperature. Add 10 mL to 30 mL of n-heptane accurately, shake for 2 min, then add saturated sodium chloride aqueous solution and allow to stand for separation. Pipette approximately 5 mL of the upper n-heptane extract into a 25 mL test tube, add approximately 3 g to 5 g of anhydrous sodium sulfate, shake for 1 min, let stand for 5 min, and then pipette the upper solution into a sample vial for analysis.

[0076] Chromatographic determination: Single fatty acid methyl ester standard solutions and mixed fatty acid methyl ester standard solutions were injected separately into the gas chromatograph for qualitative analysis of the chromatographic peaks. Capillary column: Poly(dicyandipropylsiloxane) strongly polar stationary phase, column length 100 m, inner diameter 0.25 mm, film thickness 0.2 μm. Injector temperature: 270 ℃. Detector temperature: 280 ℃. Temperature program: Initial temperature 100 ℃, hold for 13 min; 100 ℃ ~ 180 ℃, ramp rate 10 ℃ / min, hold for 6 min; 180 ℃ ~ 200 ℃, ramp rate 1 ℃ / min, hold for 20 min; 200 ℃ ~ 230 ℃, ramp rate 4 ℃ / min, hold for 10.5 min. Carrier gas: Nitrogen. Split ratio: 100:1. Injection volume: 1.0 μL.

[0077] The percentage of a specific fatty acid in the total fatty acids in a sample, Yi, is calculated using the following formula. The content of a given component i is calculated by measuring the percentage of the corresponding peak area relative to the sum of the peak areas of all components:

[0078]

[0079] In the formula:

[0080] Y i —The percentage of a specific fatty acid in the total fatty acids in the sample, expressed as %.

[0081] A Si ———Peak areas of each fatty acid methyl ester in the sample test solution;

[0082] F FAMEi-FAi ——— The coefficient for the conversion of fatty acid methyl ester i into fatty acids;

[0083] ∑A Si ———The sum of the peak areas of each fatty acid methyl ester in the sample test solution.

[0084] The result should be rounded to 3 significant figures.

[0085] Test results show that batch 2 of fermented artemisia annua oil mainly contains oily components, with linoleic acid (cis-9,12-octadecadienoic acid) accounting for approximately 50%, which is considered a medium-to-high level among plant oils. Linoleic acid, an Omega-6 polyunsaturated fatty acid, is an essential component that the human body cannot synthesize on its own. Studies have found that linoleic acid has various effects in skincare, including improving the skin barrier, soothing inflammation, and anti-oxidation. The high linoleic acid content in fermented artemisia annua oil provides a material basis for its skincare effects. As the main component of fermented artemisia annua oil, when used as a product testing parameter, a relative content of linoleic acid ≥35% in the fatty acid composition of fermented artemisia annua oil meets the requirements. The results are shown in Tables 1-2.

[0086] Table 1

[0087]

[0088] Table 2: Fatty acid composition and relative content in fermented Artemisia annua oil

[0089]

[0090] HPLC method for determining the content of artemisinin in fermented artemisia annua oil

[0091] Experimental apparatus:

[0092] 1. Waters ARC high-performance liquid chromatograph with diode array detector (Waters);

[0093] 2. XS205 analytical balance (METTLER TOLEDO);

[0094] 3. KQ-800DE CNC ultrasonic cleaner (Kunshan Ultrasonic Instrument Co., Ltd.)

[0095] Chromatographic conditions:

[0096] Column: Agilent ZORBAX SB-C18, 250 mm × 4.6 mm × 5 μm;

[0097] Mobile phase: Acetonitrile (90%) - 0.1% phosphoric acid aqueous solution (10%);

[0098] Flow rate: 1.0 mL / min;

[0099] Column temperature: 30℃;

[0100] Wavelength: 220 nm;

[0101] Injection volume: 10 μL.

[0102] Testing steps:

[0103] Preparation of artemisinin standard stock solution (400 mg / L): Weigh 20 mg of artemisinin standard (Nature Standard, purity ≥98.0%) (accurate to 0.01 mg), dissolve in methanol and dilute to 50 mL.

[0104] Preparation and determination of artemisinin standard working solution: Accurately transfer 1 mL of artemisinin standard stock solution and dilute to 10 mL with methanol to obtain a standard working solution with a concentration of 40 mg / L. Perform the determination according to the chromatographic conditions described above.

[0105] Sample processing and determination:

[0106] Weigh 0.25 g (accurate to 0.1 mg) of the sample into a 10 mL stoppered colorimetric tube, add 8 mL of methanol, and extract by sonication for 20 min. Make up to volume with methanol, shake well, and filter the liquid fraction through a 0.45 μm filter membrane. Then, determine the chromatographic content according to the above conditions. Calculate the artemisinic acid content in the sample using the single-point external standard method.

[0107] The results are shown in Table 3.

[0108] Table 3

[0109]

[0110] As shown in the table above, all batches of fermented artemisia annua oil contained artemisinic acid, a characteristic component of artemisia annua, with a content greater than 0.03% by weight, which can be used as a characteristic indicator of fermented artemisia annua oil. Artemisinic acid is an important sesquiterpene compound extracted from artemisia annua (Artemisia annua), possessing various biological activities, including antimalarial activity, antipyretic effects, antibacterial and anti-inflammatory activities, and anti-glycation effects. The presence of a certain amount of artemisinic acid in fermented artemisia annua oil may be one of the reasons why fermented artemisia annua oil exhibits new therapeutic effects.

[0111] Acid value, peroxide value, and density testing

[0112] Detection method:

[0113] The acid value test method is based on GB / T 2716, the peroxide value test method is based on GB 5009.227-2023, and the density test method is based on GB / T 611.

[0114] The test results are shown in Table 4.

[0115] Table 4

[0116]

[0117] Example 2: UVB Damage Repair Measurement

[0118] Experimental materials:

[0119] Safflower seed oil: purchased from Shanghai Zhongrui Biotechnology Co., Ltd.

[0120] Fermented Artemisia annua oil (trade name: Bifida ferment lysate fermented Artemisia annua oil, manufacturer: Hangzhou Shiguang Xinya Biotechnology Co., Ltd.).

[0121] Experimental methods:

[0122] Laboratory animal husbandry

[0123] The animal experiments in this study followed standardized husbandry procedures: the UVB group used SKH1-Hrhr genetic strain mice, and all experimental animals were housed in an SPF-grade barrier environment at Shanghai Jiao Tong University. Husbandry conditions included: stocking density ≤ 5 mice / cage; free access to sterile feed and drinking water; 12-hour circadian rhythm control; and regular replacement of sterilized bedding.

[0124] UVB mouse model construction

[0125] The mouse model used in this experiment had a genetic background of SKH1-Hrhr. After a one-week adaptation period, 7-week-old male SKH1 Hairless Mice were randomly divided into three groups as follows: (i) normal control group (no ultraviolet radiation, CON); (ii) ultraviolet radiation control group (ultraviolet radiation, UVB group).

[0126] UVB mouse oil application regimen

[0127] Seven-week-old male SKH1 hairless mice were randomly assigned to: (1) a UV irradiation control group (UVB group); (2) a UV irradiation group and a 100 μL application of safflower seed oil group (UVB + safflower seed oil); (3) a UV irradiation group and a 100 μL application of fermented artemisia annua oil group (UVB + fermented artemisia annua oil); and (4) a UV irradiation group and a compound preparation group (safflower seed oil: fermented artemisia annua oil = 1:1) (UVB + compound preparation). The oil was applied once daily, and the mice were pretreated with the oil at 2000 J / m³ half an hour before the start of UV irradiation. 2 UVB was applied every other day for one week (a total of 4 times). During the experiment, the backs of mice were photographed every other day to observe their phenotype for signs such as redness, swelling, sunburn, and peeling.

[0128] This study used the Scientz 03-II UV crosslinker for UVB irradiation.

[0129] Paraffin sections of skin tissue

[0130] 1. Fixation: Immediately immerse isolated mouse back skin tissue in 4% PFA for 24 hours for fixation, and wash with PBS for 10 minutes three times.

[0131] 2. Dehydration and clearing: Dehydration with graded ethanol (70%→80%→90%→95%→100%), 1-2 hours per grade; dehydration with xylene twice, 30 minutes each time.

[0132] 3. Paraffin Immersion: Immerse the tissue in molten paraffin and then place it in an oven. Change the paraffin solution twice during this process, with an interval of 2 hours between each change.

[0133] 4. Embedding: Place the tissue in an embedding cassette, wait for the paraffin to solidify at room temperature, then remove the embedding cassette, trim the paraffin block into a cube, and fix it on the embedding frame;

[0134] 5. Sectioning: The section thickness is 6-8 μm. After the cut paraffin sections float on the water surface for about 5 minutes, they are slowly lifted up with a positively charged anti-detachment slide to avoid generating air bubbles.

[0135] 6. Baking: Baking the slices in a 42°C baking machine overnight, then storing them at room temperature in a slicing box.

[0136] frozen sections of skin tissue

[0137] 1. Pre-cooling the machine: Set the object temperature (OT) of the cryostat to -22°C and the chamber temperature (CT) to -20°C in advance.

[0138] 2. Tissue fixation: Isolated mouse back skin tissue was fixed in 4% PFA for 24 hours and washed with PBS for 10 minutes three times.

[0139] 3. 30% sucrose solution: Place the tissue in a 30% sucrose solution (prepared with PBS) at 4°C and shake at 4°C for 24 hours.

[0140] 4. OCT: Place the tissue in an OCT chamber at 4°C overnight.

[0141] 5. Embedding: Immerse the tissue in a plastic embedding cassette containing OCT, remove air bubbles, and then place the plastic embedding cassette horizontally at -20°C. After the OCT solidifies, store it at -80°C as soon as possible.

[0142] 6. Sectioning: Remove the OCT block from the embedding cassette and section it. The thickness of the immunofluorescence stained slide should be 10~15 μm.

[0143] Hematoxylin-eosin staining (HE)

[0144] 1. Dewaxing and hydration

[0145] Dewaxing: The cut paraffin tissue was soaked in xylene twice for 10 minutes each time, and the process was carried out in a fume hood.

[0146] Hydration: Gradual ethanol (100%→95%→90%→80%→70%), each for 5 minutes, followed by rinsing twice with distilled water for 5 minutes.

[0147] 2. Hematoxylin staining

[0148] Hematoxylin staining: Filter hematoxylin through a 0.22 μm filter membrane. Immerse the tissue in the hematoxylin staining solution for 5 minutes, taking care to avoid light. After staining, rinse with running water at low speed for 5 minutes to remove any excess stain.

[0149] 3. Differentiation and Return to Blue

[0150] Differentiation: Soak in hydrochloric acid and ethanol for 10 seconds until the slices turn red and the cell nuclei are clear.

[0151] Blueing: Rinse with low-speed water for 15 minutes.

[0152] 4. Eosin staining

[0153] Eosin staining: Immerse in 1% eosin staining solution for 20 seconds (the cytoplasm will turn pink), then immediately wash in 95% anhydrous ethanol for 5 minutes to decolorize.

[0154] 5. Dehydration and Transparency

[0155] Dehydration: Gradient 100% anhydrous ethanol for 5 minutes.

[0156] Transparent: Soak in xylene for 10 minutes twice in a fume hood.

[0157] 6. Sealing

[0158] Mounting: Add a drop of neutral resin, place a coverslip on top, and apply clear nail polish around the coverslip to secure it. Avoid air bubbles and store at room temperature until dry.

[0159] Immunofluorescence (IF) staining

[0160] 1. Paraffin sections:

[0161] Dewaxing: Immerse the cut paraffin slices in xylene twice, 10 minutes each time, in a fume hood.

[0162] Hydration: Gradient ethanol (100%→95%→90%→80%→70%), each for 5 minutes, followed by ddH2O rinsing for 5 minutes, twice.

[0163] Heat retrieval: Place the slides in antigen retrieval solution and heat retrieval at 99°C for 20 min. After cooling to room temperature, wash three times with PBST for 10 min each time.

[0164] 2. Frozen slices:

[0165] Remove the frozen sections from -80°C beforehand, bake them on a 42°C slide oven for a few minutes, and then carefully wash them three times with PBS for 10 minutes each time, taking care to avoid tissue detachment.

[0166] 3. The following are the common steps for paraffin sections and frozen sections:

[0167] (1) Carefully wipe the water stains around the section, carefully circle the tissue with a histochemical pen, and then immediately add blocking solution. In a humidified chamber, block at room temperature for 1 hour, being careful not to let the section dry.

[0168] (2). Add 20 μL of primary antibody to each tissue and incubate overnight (12-16 h) at 4°C in a humidified chamber.

[0169] (3) On the second day, take out the wet box and wash the slides with PBST 3 times, 10 min each time.

[0170] (4) Add fluorescent secondary antibody and incubate in a humidified chamber at room temperature for 2 h, taking care to avoid light.

[0171] (5) Wash with PBST 3 times, 10 min each time.

[0172] (6) Mount the slide with 10 μg / ml DAPI solution, fix the edges of the coverslip with nail polish, and store in the dark.

[0173] (7) Image acquisition was performed using a Leica upright fluorescence confocal microscope and LAS X software.

[0174] Reagents and formulations for immunofluorescence staining

[0175]

[0176] Antibodies used in immunofluorescence staining

[0177]

[0178] RNA extraction and reverse transcription

[0179] This study used the Trizol method to extract total RNA. Throughout the experiment, consumables such as RNA-free pipette tips, centrifuge tubes, and EP tubes were used. Before the operation, the laboratory table and instruments were thoroughly wiped with a cleaning agent containing RNase / DNase inactivating agent (Labshark, 130114007) to strictly prevent RNase contamination.

[0180] 1. Skin sample / cell processing:

[0181] A. Epidermal Sample Preparation: After removing the subcutaneous fat layer, the epidermis was laid flat with the surface facing upwards on a 0.25% trypsin solution (digested at 37°C for 1 h) to separate the epidermis from the dermis. After mechanical separation with ophthalmic scissors, the tissue was lysed at room temperature for 20 min (with intermittent shaking) at a ratio of 50-100 mg tissue / 500 μL TRIZOL. The volume of the tissue sample was strictly controlled to be less than 10% of the TRIZOL volume.

[0182] B. Whole Skin Tissue: After obtaining whole skin tissue, use ophthalmic scissors to cut the tissue into small pieces as much as possible, then use a tissue homogenizer to further break it up. Add 500 μL of TRIZOL to the whole skin tissue and incubate at room temperature for 20 min to fully lyse, shaking the tissue multiple times during this period. Ensure that the sample volume does not exceed 10% of the TRIZOL volume.

[0183] C. Cells: After aspirating the cell culture medium, gently wash three times with PBS for 5 minutes each time. Then add 300 μL of TRIZOL to each well and lyse at room temperature for 20 minutes. After the cells have completely detached from the culture dish, transfer them to 1.5 mL centrifuge tubes for subsequent RNA extraction.

[0184] 2. Chloroform phase separation: Add chloroform to TRIZOL liquid at a 1:1 volume ratio, shake vigorously for 15 seconds to form an emulsion, and let stand at room temperature for 10 min. Centrifuge at 12000 g for 15 min at 4℃ to separate the phases.

[0185] 3. RNA precipitation: Pipette 250 μL of supernatant into a new EP tube, add isopropanol at a 1:1 volume ratio, gently invert to mix, and incubate at room temperature for 10 min after thorough mixing with isopropanol. Centrifuge at 12000 g for 15 min at 4℃ to obtain the precipitate.

[0186] 4. Ethanol washing: Discard the supernatant, add 1 mL of 75% ethanol (RNase-free ethanol:DEPC water = 3:1) to resuspend the precipitate, gently pipette, centrifuge at 7500 g for 5 min at 4°C, repeat the washing twice, and a white precipitate can be seen after centrifugation.

[0187] 5. RNA dissolution: Remove residual ethanol with a pipette, and air dry for 20 min to evaporate the remaining ethanol until the white RNA precipitate becomes clear; add 20-50 μL of DEPC water preheated to 55°C, and then place in a 4°C refrigerator for 30 min to dissolve.

[0188] 6. Quality Control: After mixing, use a Nanodrop instrument to test purity. After zeroing with DEPC water, test RNA concentration. Note that the RNA solution should be thoroughly mixed before testing. The A260 / 280 ratio should be close to 2.0, and the A260 / 230 ratio should be greater than 2.0. Qualified samples should be used immediately for cDNA synthesis or frozen at -80℃.

[0189] 7. Reverse transcription was performed using the SuperScript First-Strand Synthesis Kit (Invitrogen).

[0190] a. Prepare the reactants according to the following proportions, and gently mix the liquid with a shaker.

[0191]

[0192] b. After the first step of the reaction, add 4 μl of 5×HiScript III qRT SuperMix to each tube of reaction mixture. After low-speed centrifugation, set the PCR instrument program as follows: maintain 37℃ for 15 min to complete reverse transcription in the first stage, followed by inactivation of reverse transcriptase at 85℃ for 5 sec. Aliquot the cDNA product into sterile EP tubes, label them, and store them at -20℃ for a short period.

[0193] Real-time quantitative PCR (RT-PCR)

[0194] 1. The real-time PCR primers are as follows:

[0195]

[0196] 2. cDNA template normalization: Adjust the cDNA concentration according to the expression abundance of the target gene to ensure that the 18S internal reference Ct value is controlled within the 8-13 cycle range.

[0197] 3. Amplification system construction: The reaction system was prepared according to the manufacturer's instructions using SYBR Green premixed buffer (FastStart). Three replicates were used in a 96-well qPCR plate. After amplification, the relative expression level of the target gene was calculated using the ΔΔCt method.

[0198] RT-PCR reaction system

[0199]

[0200] 4. Apply the sealing film and use a scraper to remove air bubbles.

[0201] 5. After centrifuging the 5.96-well plates at 1000 rpm for 1 min, the reaction was carried out on a Varioskan LUX machine.

[0202] RT-PCR reaction conditions

[0203]

[0204] Comparative transcriptome sequencing (RNA-seq)

[0205] Transcriptomics sequencing was performed by BGI Genomics Co., Ltd. Post-sequencing data analysis was conducted using the Dr.Tom platform (biosys.bgi.com), including principal component analysis (PCA) plots, differentially expressed gene volcano plots, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis plots and heatmaps. Differentially expressed genes (DEGs) were identified using the DEGseq2 method and screened using criteria of q-value ≤ 0.05 and |log2FC| ≥ 1 (fold change, FC).

[0206] Data Statistical Analysis

[0207] Statistical analyses were performed using Prism software (GraphPad). All statistical analyses were performed using unpaired two-tailed t-tests or two-dimensional ANOVA. Where applicable, data are expressed as SEM ± mean. p-values ​​indicate differences between groups (*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, ns indicates no statistical significance).

[0208] Experimental results:

[0209] Table 5 shows the experimental group information.

[0210] Table 5

[0211]

[0212] Figure 1 The results of photographs taken on days 0, 1, 3, 5, and 7 show the UV-irradiated control group (UV-CON) and various UV-irradiated groups (including UV+safflower seed oil (SSO), UV+fermented artemisia annua oil (FAAO), UV+(safflower seed oil:fermented artemisia annua oil = 1:1), and UV+(safflower seed oil:fermented artemisia annua oil = 3:1). Seven consecutive days of UVB exposure induced significant inflammatory responses in mice, including erythema, edema, and scaly desquamation. Groups 1, 2, 3, and 4 all showed varying degrees of erythema reduction on day 7, with groups 3 and 4 exhibiting significant inhibition of skin edema and reduction of desquamation, maintaining a stable barrier protection phenotype throughout the experimental period. Figure 1 As shown, sample groups 3 and 4 exhibited more significant effects in inhibiting skin edema and reducing desquamation in the UV model.

[0213] Figure 2 Microscopic images of the normal control group (no UV), the ultraviolet irradiation control group (UV-CON), and various ultraviolet irradiation groups (including UV+safflower seed oil (SSO), UVB+fermented artemisia annua oil (FAAO), UV+(safflower seed oil:fermented artemisia annua oil = 1:1) and UV+(safflower seed oil:fermented artemisia annua oil = 3:1) are shown.

[0214] Figure 3The study shows the epidermal thickness of the normal control group (no UV), the UV-irradiated control group (UV-CON), and various UV-irradiated groups (including UV + safflower seed oil (SSO), UVB + fermented artemisia annua oil (FAAO), UV + (safflower seed oil: fermented artemisia annua oil = 1:1)) and UV + (safflower seed oil: fermented artemisia annua oil = 3:1). HE staining analysis showed that UVB irradiation could induce abnormal thickening of the epidermal layer. In HE-stained skin sections taken on day 7, all sample groups showed significant relief of this pathological phenomenon. The epidermal thickness recovery was particularly significant in sample groups 3 and 4, indicating that the synergistic effect significantly enhanced the repair efficacy on the integrity of the epidermal structure and barrier function.

[0215] like Figure 2-3 As shown, sample groups 3 and 4 significantly alleviated the abnormal thickening of the epidermis caused by UV radiation in the UV model.

[0216] Figure 4-10 The transcriptomic results for sample group 3 are shown.

[0217] This study used transcriptome sequencing technology to compare and analyze the gene expression characteristics of the control group (CON), the UVB damage group (UVB), and sample group 3 (UVB_Compound). Principal component analysis (PCA) showed that UVB radiation caused a significant shift in the skin gene expression profile. The CON and UVB samples were clearly separated in the PC1 / PC2 space, while the transcriptome characteristics of the UVB_Compound group were closer to those of the CON group, indicating that the compound preparation could partially reverse the UVB-induced gene expression disorder. Differentially expressed genes (DEGs) analysis further revealed that a total of 1743 DEGs (|log2FC| > 1, adjusted q < 0.05) were identified in the UVB / CON group, while the number of differentially expressed genes increased to 4086 in the UVB_Compound / UVB group, of which 1240 DEGs were shared by both groups, suggesting that these genes may be involved in both the UVB damage process and the repair regulatory network.

[0218] KEGG pathway enrichment analysis of 1240 shared DEGs showed significant enrichment in pathways such as ECM-receptor interaction, protein digestion and absorption, VEGF signaling pathway, and alpha-linolenic acid metabolism. Heatmap analysis of genes related to the VEGF signaling pathway revealed significant upregulation of pro-inflammatory genes (VEGFα) in the UVB group, while the activity of this pathway was significantly inhibited after intervention with the compound preparation. This result suggests that the compound preparation may alleviate skin barrier damage by inhibiting VEGF-mediated angiogenesis and the inflammatory cascade. Furthermore, heatmap analysis of genes related to the ECM-receptor interaction pathway showed significant downregulation of key collagen synthesis genes (COL1A1, COL5A1) in the UVB group, leading to dermal structural damage; the compound preparation reversed this trend, restoring gene expression to near-normal levels, indicating that it repairs the skin's mechanical barrier function by promoting collagen synthesis and matrix remodeling.

[0219] In summary, the dual mechanism by which sample group 3 repairs UVB damage is: 1) by downregulating VEGF pathway activity to inhibit the inflammatory response and reduce barrier function damage; 2) by activating ECM-related gene expression to reshape the collagen network and restore skin structural homeostasis.

[0220] Figure 11 Immunofluorescence results were shown. Immunofluorescence staining revealed a significant increase in F4 / 80-positive macrophage infiltration in mouse skin tissue exposed to UVB for 7 consecutive days compared to the control group, indicating that UVB radiation can induce activation of innate skin immune cells and the formation of a local inflammatory microenvironment. Notably, local intervention in groups 1, 2, 3, and 4 effectively reversed the UVB-induced upregulation of F4 / 80 expression, with the compound preparation group showing the most significant inhibitory effect, suggesting that different lipid components may exert anti-inflammatory effects through synergistic regulation of macrophage chemotaxis or activation pathways. Figure 5 As shown, sample groups 3 and 4 can more effectively reverse the upregulation of F4 / 80 expression caused by UVB, and can exert anti-inflammatory effects by synergistically regulating macrophage chemotaxis or activation pathways.

[0221] Figure 12The results of qRT-PCR analysis of skin tissue are shown. The results indicated that UVB irradiation significantly increased the expression levels of TNF-α, IL-6, and IL-1β, while the expression of all three was significantly inhibited after intervention in sample groups 3 and 4. This result for sample group 3 is highly consistent with the downregulation trend of related pro-inflammatory genes in RNA-seq data, confirming that the compound preparation can improve the skin's immune microenvironment by inhibiting the expression of inflammatory factors at multiple targets. Figure 6 As shown, sample group 3 can inhibit the expression of inflammatory factors IL-6, IL-1β and TNF-α.

[0222] The oil composition described in this invention can be used as a functional additive in topical skin agents, preferably cosmetic compositions, including but not limited to the preparation of products in dosage forms such as creams, lotions, gels, toners, serums, masks, eye creams, aerosols (cleansing foams), shower gels, and facial cleansers. The oil composition constitutes 0.0001%-100% (w / w) of the topical skin agent by weight. A preferred weight percentage is 0.001%-20% (w / w). A more preferred weight percentage is 0.001%-10% (w / w). The most preferred weight percentage is 0.01%-5% (w / w).

[0223] The following are specific examples of the application of oil-based compositions in topical skin preparations, along with the formulations and preparation methods of these dosage forms. Specific applications are as follows:

[0224] Application Example 1: Preparation of Face Cream

[0225]

[0226] Application Example 2: Emulsion Preparation

[0227]

[0228] Application Example 3: Preparation of Eye Cream

[0229]

[0230] Application Example 4: Preparation of Facial Masks

[0231]

[0232] Application Example 5: Preparation of Serum

[0233]

[0234] Application Example 6: Preparation of Essential Oils

[0235]

Claims

1. UVB damage repair application of an oil composition comprising safflower seed oil and fermented artemisia oil, characterized in that, The fermented artemisia oil was prepared by the following method: (a) Artemisia annua was extracted using supercritical CO2 extraction; (b) Fermentation, using Bifida ferment lysate; (c) Fermented artemisia oil was obtained after separation; The bifida ferment lysate is a Bifidobacterium, selected from: Bifidobacterium adolescentis, Bifidobacterium animalis subsp. animalis, Bifidobacterium animalis subsp. lactis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum subsp. longis, or Bifidobacterium longum subsp. infantis.

2. Use according to claim 1, wherein The content of artemisinic acid in the fermented artemisia oil is ≥ 0.03% by weight, the acid value of the fermented artemisia oil is ≤ 2.5 mg / g, the peroxide value of the fermented artemisia oil is ≤ 0.650 g / 100 g, the density of the fermented artemisia oil is 0.9-0.95 g / cm 3 .

3. The use according to claim 1, wherein The fatty acid composition of the fermented artemisia annua oil contains ≥35% by weight of linoleic acid and ≥0.05% by weight of artemisinin.

4. The use according to claim 1, wherein The weight ratio of safflower seed oil to fermented artemisia oil in the oil composition is 1:1 to 3:

1.

5. The use according to claim 1, wherein The applications include one or more of the following: (i) Inhibits skin edema and reduces desquamation after UVB exposure; (ii) Alleviate abnormal thickening of the epidermis caused by UVB; (iii) Downregulating VEGF pathway activity inhibits inflammatory response and reduces barrier function damage; (iv) Activating the expression of ECM-related genes remodels the collagen network and restores skin structural homeostasis; (v) Synergistically regulate macrophage chemotaxis or activation pathways to exert anti-inflammatory effects; (vi) Inhibit the expression of inflammatory factors IL-6, IL-1β and TNF-α.

6. Use of an oil composition comprising safflower seed oil and fermented artemisia oil in the preparation of a skin external agent having a UVB damage repair effect, characterized in that, The fermented artemisia oil was prepared by the following method: (a) Artemisia annua was extracted using supercritical CO2 extraction; (b) Fermentation, using Bifida ferment lysate; (c) Fermented artemisia oil was obtained after separation; The bifida ferment lysate is a Bifidobacterium, selected from: Bifidobacterium adolescentis, Bifidobacterium animalis subsp. animalis, Bifidobacterium animalis subsp. lactis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum subsp. longis, or Bifidobacterium longum subsp. infantis.

7. Use according to claim 6, wherein The weight ratio of safflower seed oil to fermented artemisia oil in the oil composition is 1:1 to 3:

1.

8. The use according to claim 6, wherein The applications include one or more of the following: (i) Inhibits skin edema and reduces desquamation after UVB exposure; (ii) Alleviate abnormal thickening of the epidermis caused by UVB; (iii) Downregulating VEGF pathway activity inhibits inflammatory response and reduces barrier function damage; (iv) Activating the expression of ECM-related genes remodels the collagen network and restores skin structural homeostasis; (v) Synergistically regulate macrophage chemotaxis or activation pathways to exert anti-inflammatory effects; (vi) Inhibit the expression of inflammatory factors IL-6, IL-1β and TNF-α.

9. The use according to claim 6, wherein The content of the oil composition in the topical skin preparation is 0.001-100% by weight.

10. The use according to claim 6, wherein The oil composition is present in the topical skin preparation at a concentration of 0.01-5% by weight.

11. Use according to claim 6, wherein The topical skin agent is selected from: face cream, lotion, gel, toner, serum, mask, eye cream, aerosol cleansing foam, spray, shower gel, or facial cleanser.

Images